Zheng Quan Ri Bao Wang·2025-05-20 12:59Core Viewpoint - The collaboration between Sanofi and Pfizer for the dual-specific antibody SSGJ-707 marks a significant step in the global commercialization of innovative cancer therapies, enhancing the international recognition and accessibility of Sanofi's products [1][2]. Company Summary - Sanofi and its affiliates granted Pfizer exclusive global rights (excluding mainland China) for the development, production, and commercialization of the dual-specific antibody SSGJ-707, with Pfizer retaining rights for commercialization in mainland China through additional payments [1]. - Pfizer will pay an upfront non-refundable fee of $1.25 billion, with potential milestone payments reaching up to $4.8 billion based on development, regulatory approval, and sales, along with a double-digit percentage sales share based on product sales in authorized regions [1]. - The antibody SSGJ-707 targets PD-1 and VEGF, having received breakthrough therapy designation from the National Medical Products Administration for treating advanced non-small cell lung cancer (NSCLC) [1][2]. Industry Summary - The collaboration signifies recognition of Sanofi's dual-specific antibody research platform by a leading international company, which is expected to enhance the global reach and acceptance of its products [2]. - The SSGJ-707 is currently in Phase III clinical trials for NSCLC and Phase II for other indications, indicating a robust pipeline for Sanofi's innovative therapies [2]. - The trend of Chinese innovative drug companies entering into licensing agreements with multinational pharmaceutical companies is growing, driven by the increasing recognition of Chinese innovation and the need for multinational firms to address patent cliffs [3][4].